MA47106A - Formulations d'anticorps anti-tnf alpha - Google Patents
Formulations d'anticorps anti-tnf alphaInfo
- Publication number
- MA47106A MA47106A MA047106A MA47106A MA47106A MA 47106 A MA47106 A MA 47106A MA 047106 A MA047106 A MA 047106A MA 47106 A MA47106 A MA 47106A MA 47106 A MA47106 A MA 47106A
- Authority
- MA
- Morocco
- Prior art keywords
- tnf alpha
- antibody formulations
- alpha antibody
- formulations
- tnf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662437640P | 2016-12-21 | 2016-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47106A true MA47106A (fr) | 2019-10-30 |
Family
ID=61006357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047106A MA47106A (fr) | 2016-12-21 | 2017-12-20 | Formulations d'anticorps anti-tnf alpha |
Country Status (4)
Country | Link |
---|---|
US (2) | US20200087390A1 (fr) |
EP (3) | EP4467565A2 (fr) |
MA (1) | MA47106A (fr) |
WO (1) | WO2018119142A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020216847A1 (fr) * | 2019-04-23 | 2020-10-29 | Sanofi | Formulations d'anticorps stables et à faible viscosité et leurs utilisations |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
EP4384217A1 (fr) * | 2021-08-12 | 2024-06-19 | Amgen Inc. | Formulations d'anticorps |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
MX2015003007A (es) * | 2012-09-07 | 2015-06-05 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab. |
US9085618B2 (en) * | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
SI2946765T1 (sl) * | 2014-05-23 | 2016-11-30 | Ares Trading S.A. | Tekoči farmacevtski sestavek |
HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
WO2016103093A1 (fr) * | 2014-12-23 | 2016-06-30 | Pfizer Inc. | Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha |
US20180016333A1 (en) * | 2015-01-28 | 2018-01-18 | Mabxience, S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
RU2017131618A (ru) * | 2015-02-13 | 2019-03-13 | Санофи | Стабильный жидкий состав для моноклональных антител |
WO2016162819A1 (fr) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha |
-
2017
- 2017-12-20 MA MA047106A patent/MA47106A/fr unknown
- 2017-12-20 US US16/471,492 patent/US20200087390A1/en not_active Abandoned
- 2017-12-20 WO PCT/US2017/067723 patent/WO2018119142A1/fr unknown
- 2017-12-20 EP EP24193070.0A patent/EP4467565A2/fr active Pending
- 2017-12-20 EP EP17832444.8A patent/EP3558363A1/fr not_active Withdrawn
- 2017-12-20 EP EP20211821.2A patent/EP3824906A1/fr not_active Withdrawn
-
2022
- 2022-08-19 US US17/820,958 patent/US20230151086A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3824906A1 (fr) | 2021-05-26 |
WO2018119142A1 (fr) | 2018-06-28 |
EP3558363A1 (fr) | 2019-10-30 |
US20230151086A1 (en) | 2023-05-18 |
EP4467565A2 (fr) | 2024-11-27 |
US20200087390A1 (en) | 2020-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49043A (fr) | Formulation stable d'anticorps | |
EP3903817A4 (fr) | Nouvel anticorps anti-ccr8 | |
MA52884A (fr) | Anticorps anti-il-11 | |
MA53434A (fr) | Anticorps anti-tigit | |
MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
EP3359573A4 (fr) | Marquage d'anticorps | |
MA47694A (fr) | Anticorps anti-tigit | |
MA49034A (fr) | Anticorps anti-lag3 | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
EP3430731A4 (fr) | Architecture d'iugw | |
EP3423089A4 (fr) | Anticorps anti-tigit | |
MA44381A (fr) | Format d'anticorps hétérodimères multispécifiques | |
MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
DK3504241T3 (da) | Anti-cd3-antistofformuleringer | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
MA49749A (fr) | Anticorps anti-cd137 | |
MA51903A (fr) | Formulations d'anticorps b7-h4 | |
EP3328429A4 (fr) | Peptides et anticorps pour l'élimination de biofilms | |
MA44054A (fr) | Plateforme d'anticorps bispécifique | |
MA52152A (fr) | Anticorps | |
EP3618865A4 (fr) | Anticorps humain anti-sémaphorine 4d | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha |